US FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma - Markets Insider

US FDA Grants Priority Review for Daratumumab in Front Line Multiple MyelomaMarkets InsiderIn August

» » US FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma - Markets Insider , ago, 1146 view
Subscribe to our Facebook Bot


US FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
Markets Insider
In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab. ?The granting of priority review to the submission of daratumumab in front line multiple myeloma is an important ...

and more »

Read more

2018-02-10T09:02:04Z 250250
Dragplus